facilitated by a compartment of dynamic, heterogeneous liver progenitor cells (LPCs), 2 which in rodents are often called oval cells. LPCs are rarely detected in healthy tissue, but once activated, they proliferate and migrate into the parenchyma and differentiate into either cholangiocytes or hepatocytes. This process, unlike hepatocyte-mediated liver regeneration, is relatively poorly understood. Several factors mediating the LPC response to injury have been identified, including tumor necrosis factor (TNF), lymphotoxin b (LTb), interferon c (IFNc), and transforming growth factor b, among others [3] [4] [5] [6] [7] ; however, the mechanisms by which these mediators elicit their effects remain largely unknown. Thus, no definitive LPC growth factor has been described to date.
In this respect, the 2005 report by Jakubowski and coworkers 8 was a milestone publication; it proposed a TNF family member, tumor necrosis factor-like weak inducer of apoptosis (TWEAK), as a direct LPC mitogen. Like most TNF superfamily ligands, TWEAK [also known as tumor necrosis factor (ligand) superfamily member 12, CD255, or previously APO3 ligand] is initially synthesized as a type II transmembrane protein that can be cleaved into a soluble cytokine. 9 TWEAK, a noncovalent homotrimer, mediates its activity through binding to a 14-kDA type I transmembrane receptor termed fibroblast growth factor-inducible 14 (Fn14). 10 Fn14 does not possess intrinsic protein kinase activity. Instead, it associates with tumor necrosis factor receptor-associated factor (TRAF) adaptor molecules and activates nuclear factor kappa light chain enhancer of activated B cells (NFjB) and the extracellular signalregulated kinase and c-Jun N-terminal kinase mitogenactivated protein kinase pathways. 11, 12 TWEAK regulates a diverse range of cellular processes, including proliferation, differentiation, migration, cell survival, and cell death, and has also been shown to act as a proangiogenic and proinflammatory factor. 13 Although TWEAK is almost ubiquitously expressed in adult tissues, including the liver, its cognate receptor is barely detectable in hepatic tissue except during injury and repair. Feng et al. 14 reported rapid induction of Fn14 expression during the early phases of regeneration following partial hepatectomy. The authors also investigated liver cancer-derived cell lines, and interestingly, Fn14 overexpression was mainly found in the poorly differentiated lines; this hinted at possible involvement in progenitor cells. This hypothesized relationship between LPCs and Fn14 signaling was strengthened by experiments described by Jakubowski and coworkers. 8 In their study, it was demonstrated that hepatic TWEAK overexpression, after transgenic or adenoviral delivery, induces an LPC response; knockout (KO) of TWEAK/Fn14 inhibits the appearance of LPCs in an experimental model of oval cell proliferation. Furthermore, TWEAK directly induces proliferation of a biliary epithelial cell line with progenitor-like characteristics. LPCs consist of a heterogeneous cellular compartment, with different discrete subsets potentially being activated under various injury contexts. Thus, we wished to further explore the relationship between TWEAK and LPCs with a different in vivo model of hepatic injury and LPC proliferation developed in our laboratory. 15 Additionally, we aimed to investigate the effects of TWEAK on LPC lines in vitro. We now demonstrate that TWEAK directly stimulates LPC mitosis in an Fn14-dependent and NFjB-dependent fashion and that this pathway plays a major role in the rapid growth phase of the LPC response to cholinedeficient, ethionine-supplemented (CDE) diet-induced injury and re-generation.
Materials and Methods
Animal Experimentation. Fn14 KO mice and respective inbred wildtype (WT) animals were used as previously described. 16 For all other experiments, C57BL/6 mice were obtained from ARC (Western Australia). Four-week-old, male mice were administered a CDE diet. 15 Control animals received normal laboratory chow and drinking water. For TWEAK administration experiments (single injection), recombinant human tumor necrosis factor-like weak inducer of apoptosis (rhTWEAK; Biogen Idec, Inc., Cambridge, MA 17 ) or vehicle (0.1% bovine serum albumin in normal saline) was injected intraperitoneally into 2-week-CDE-pretreated mice at a final dose of 0.02 lg/ g of body weight. All procedures were performed in strict compliance with the guidelines set by the National Health and Medical Research Council of Australia and the University of Western Australia Animal Ethics Committee.
Primary LPC Isolates. Livers of 2-week-CDEtreated mice were perfused, digested, and enriched for LPCs by discontinuous Percoll gradient centrifugation, as described previously. 18 Cell Lines and Cell Culture. The murine, bipotential LPC lines-bipotential murine oval liver (BMOL) and bipotential murine oval liver-tyrosine aminotransferase (BMOL-TAT)-were established from CDEtreated livers. 18 Both lines were maintained as previously reported unless otherwise indicated. For proliferation experiments, serum and growth factor concentrations in the media were reduced to 2% fetal bovine serum (FBS), 15 ng/mL insulin-like growth factor II (IGF-II), 10 ng/mL epidermal growth factor (EGF), and 5 lg/mL insulin for three consecutive passages prior to use. Transfection was performed on 70% to 80% confluent cultures with either HiPerfect or SuperFect reagents (Qiagen, United States) according to the manufacturer's instructions.
Small Interfering RNA (siRNA) Knockdown. Knockdown of NFjB p50 was performed under RNA interference (RNAi) conditions as previously described 19 with commercial siRNAs (Qiagen) and a human/mouse siRNA starter kit (Qiagen).
Cell Proliferation. Proliferation after exposure to rhTWEAK (Biogen Idec) was assessed in vitro in a medium containing 0.5% FBS, 15 ng/mL IGF-II, 10 ng/ mL EGF, and 5 lg/mL insulin and was quantified with the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, 20 the Cellscreen system, 21 or an in vitro 5-bromo-2-deoxyuridine (BrdU) incorporation method (Calbiochem, United States). In situ, proliferation was evaluated via staining for Ki67 (Dako, United States), as previously described. 19, 22 NFjB Assay. The activity of NFjB in cell lines was measured with a green fluorescent protein (GFP) reporter transactivation assay (SABiosciences, United States) using the recommended methodology. After a 6-hour incubation step with the transfection complexes, cells were treated with rhTWEAK (Biogen Idec) for 24 hours, and GFP expression was quantitated fluorometrically and by fluorescence microscopy.
Fluorescence-Activated Cell Sorting (FACS) of Liver Leukocytes. Leukocytes were prepared from phosphate-buffered saline-perfused livers as previously described. 23 
Results
Fn14 and TWEAK Expression in the Liver. Realtime polymerase chain reaction analysis of whole liver extracts showed low levels of TWEAK mRNA in all samples, with no significant difference between experimental groups (Fig. 1A) . In both normal and CDEinjured livers, TWEAK was primarily expressed by natural killer (NK) cells and macrophages (Fig. 1B) . Fn14 mRNA expression levels were substantially increased in CDE livers by approximately 6-, 17-, and 11-fold with 1, 2, and 3 weeks of CDE treatment, respectively (Fig.  1C) . The correlation of Fn14 mRNA with LPC numbers (quantified by A6 staining and cell counting of 1-to 3-week CDE livers, as previously described) 22 produced a significant (P < 0.0001) positive correlation with a coefficient of 0.9417 (Fig. 1D) . Furthermore, primary nonparenchymal cell isolates from a 2-week CDE liver had proportions of cells positive for the LPC/biliary marker A6 (36%) and the LPC/epithelial cell marker E-cadherin (34%) similar to those for Fn14 (36%; not shown). Double immunofluorescence staining of these isolates illustrated coexpression of another accepted LPC/biliary marker, CKpan 24 ( Fig 25 illustrated that this effect is independent of the marker used.
Inflammation and Fibrosis Correlate with Reduced LPC Expansion in Fn14 Null Mice. Our group and others have previously described coregulation of inflammatory and fibrogenic responses with LPC proliferation in the CDE model. 4, 22, 26, 27 Thus, we wished to determine whether the reduction of LPC proliferation observed in Fn14 null mice correlated with these other important regenerative pathologies.
Numbers of both CD45
þ leukocytes and F4/80 þ macrophages were significantly reduced in Fn14 KO livers at 2 but not 3 weeks (Fig. 3A,B) . In accordance, expression of the key inflammatory cytokines TNF ( TWEAK Is a Direct Mitogen to LPCs In Vitro. The clonal LPC lines BMOL and BMOL-TAT 18 were confirmed to be strongly positive for the TWEAK receptor Fn14 in the majority of cells (Fig.  5A) . Treatment of BMOL and BMOL-TAT cells with rhTWEAK led to activation of the transcription factor NFjB, which was an expected outcome after stimulation of Fn14. 11, 12 NFjB activation was dosedependent, however, only at lower concentrations (Fig. 5B) .
Stimulation of growth factor-and serum-starved cells with rhTWEAK induced proliferation in a dosedependent and time-dependent fashion, as determined by Cellscreen analysis (Fig. 5C ) and confirmed by MTT assay (not shown). In agreement with the NFjB activation data, this effect was also dose-dependent only at doses up to 50 ng/mL (Fig. 5D ).
TWEAK Stimulates LPC Proliferation In Vivo. To address whether TWEAK can stimulate LPC proliferation in vivo, we administered rhTWEAK to mice with a preexisting LPC response induced by 2 weeks of CDE feeding and then measured proliferation in situ, 24 or 48 hours later, by staining for the proliferating cell marker Ki67. Hepatocyte proliferation did not differ between placebo and rhTWEAKinjected groups at either time point. In contrast, 24 hours after rhTWEAK administration, a 2-fold increase was observed in the number of Ki67-labeled nonparenchymal cells. By 48 hours post-rhTWEAK delivery, the proliferative wave had ended (Fig. 6A) . Morphologically, many cells of the Ki67-labeled, nonparenchymal cell fraction had the appearance of LPCs and were located periportally. In accordance, double staining for CKpan 24 and Ki67 illustrated that the majority of nonparenchymal cells stimulated by rhTWEAK injection were LPCs (Fig. 6B,C) . Immunofluorescent staining for leukocytes revealed a time-dependent increase in CD45 þ inflammatory cell numbers in rhTWEAK-injected animals compared to placebotreated animals (Fig. 6D) , and this is consistent with the previously demonstrated coregulation of the inflammatory response with LPC proliferation (Fig. 3) .
NFjB Mediates TWEAK/Fn14-Induced LPC Proliferation. Regenerating CDE livers showed the expected up-regulation of NFjB signaling in comparison with WT controls. Interestingly, numerous cells strongly positive for cytoplasmic and nuclear (active) NFjB were localized in periportal liver regions. Double staining of sections for A6 and NFjB demonstrated that many NFjB þ cells were represented by LPCs (Fig. 6E-G) ; this suggests that this transcription factor mediates the pro-proliferative effects of TWEAK in the CDE model. To test this hypothesis, RNAi was used to knock down the p50 NFjB subunit in the LPC lines BMOL and BMOL-TAT (which were isolated from a CDE-treated liver) before measurement of the mitotic S phase by BrdU incorporation. Transfection of p50 siRNA reduced TWEAK-induced LPC proliferation in a dose-dependent fashion. Dose-dependent proliferation of LPCs following TWEAK stimulation was not affected by transfection of a scrambled control siRNA vector (Fig. 6H) . Fig. 2 . LPC expansion is attenuated in Fn14-deficient animals. Fn14 KO or WT mice were subjected to a CDE diet to induce hepatocyte injury and stimulate the regenerative response of LPCs. After 2 weeks on the CDE diet, LPC numbers in WT livers were significantly increased versus control diet. In contrast, Fn14 KO mice exhibited only a modest enrichment of LPCs after 14 days of CDE treatment. Interestingly, however, the numbers of LPCs in the Fn14 KO livers normalized within 3 weeks on the diet, and they did not differ from the WT response at the 21-day time point. This pattern of LPC induction was evident, regardless of whether (A,D-I) A6 (A6 in red and DAPI for nuclear quantitation in blue), (B) CK19 (see Supporting Fig. 2 ), or (C) E-cadherin (see Supporting Fig. 2 ) was used to quantify the response. Data represent means 6 SEM (n ¼ 3-4). Statistical significance is represented as *P < 0.05. The dashed line signifies cell counts of control diet-fed WT mice.
Discussion
Once considered by many to be little more than a histological artifact, adult LPCs (oval cells) are now the subject of much attention because of their potential use as vectors or targets for cell or drug-based therapy 28 and their clear association with chronic hepatic disease progression. 6, 19, 29 With respect to the former, it is interesting to note that despite considerable efforts, no LPC-specific growth or differentiation factors have been identified. The characterization of TWEAK as a mitogen for LPCs not only is important for our understanding of how regenerative responses are mediated in chronic damage but also draws us one step closer to achieving selective modulation of LPC behavior for the purposes of cell therapy and regenerative medicine.
The study by Jakubowski et al. 8 showed definitively that the TWEAK ligand and its cognate receptor Fn14 mediate the behavior of at least a subset of LPCs. This was demonstrated by several approaches, including (1) gene-targeted mice, which showed a reduced presence of A6-expressing cells in an experimental model of ductular reaction, and (2) increased numbers of LPCs in transgenic mice, which overexpressed TWEAK. LPCs are recognized as being highly heterogeneous and dynamic, and several previous studies from our laboratory have illustrated selective modulation of discrete subpopulations of LPCs by cytokines. 3, 30, 31 Because the LPC compartment induced in various liver injury models may be different, we aimed to further explore the role of the TWEAK pathway in an additional in vivo model of LPC expansion and to study its effects directly on LPC lines in vitro.
Using the CDE model of hepatocellular injury and regeneration, which our laboratory pioneered for use in mice, 15 we now show that TWEAK signaling via its receptor Fn14 is essential for the early expansion of LPCs in response to CDE-induced liver injury. In livers from CDE diet-fed mice, LPCs proliferate outward from periportal regions, not in ducts or pseudoducts, but as streams of cells. We have extensively studied the dynamics of this response and shown that the LPC proliferation in this model has two phases: linear growth and maintenance. Linear growth begins between days 3 and 5 and is completed around days 12 to 16. During this phase, LPCs have a doubling time of approximately 18 hours, a cycling time typical of a stem or progenitor cell. 32 At the end of the linear growth phase, LPC numbers plateau, and only small numbers of LPCs are seen dividing (B. Knight, unpublished observations, 2009). Thus, it is interesting that Fn14 KO mice displayed significantly fewer LPCs on day 14 but not day 21; this suggests that TWEAK is important in mediating the rapid expansion of the LPC pool immediately after the onset of liver damage and is less significant in affecting their slow turnover þ ) in WT livers showed a modest (1.5-to 2-fold) enrichment in both cell types after 2 or 3 weeks of CDE feeding. This increase was attenuated in Fn14 KO animals at 14 days but rebounded by 21 days. Accordingly, mRNA expression of the proinflammatory cytokines (C) TNF, (D) IL-6, (E) IFNc, and (F) LTb, which increased in response to the CDE diet in WT mice, was suppressed in animals lacking Fn14, but again only at 2 weeks. Data represent means 6 SEM (n ¼ 3-4). Statistical significance is represented as *P < 0.05. The dashed line signifies cell counts or mRNA levels of control diet-fed WT mice.
in the latter phase of the diet response. One interpretation is that the linear LPC expansion phase is delayed by the lack of TWEAK signaling, and other pathways compensate subsequently. Many cytokines orchestrate the LPC response, and it is therefore also not surprising that a deficiency of a single cytokine inhibits but does not fully block LPC proliferation, as has been shown for CDE-fed mice deficient for TNFR1, TNF/ LTa, IFNc, or LTb. 3, 5, 6 In this respect, it is important to note that Jakubowski et al. 8 also used the 14-day time point to examine the response of Fn14 KO mice to 3,5-diethoxycarbonyl-1,4-dihydrocollidine-induced injury. Preliminary data detailing the dynamics of the LPC response in this model suggest that rapid growth also occurs between approximately days 5 and 16 (B. Knight, unpublished observations, 2009), with peak Ki67 labeling of LPCs on day 12 (Boulter et al., unpublished data, 2009). In our in vivo studies, we have not detected an increase in TWEAK mRNA expression in response to injury. Expression of TWEAK in CDE cell isolates was predominantly in NK cells and macrophages, which are known to associate physically with proliferating LPCs in CDE and other models. 33 In contrast, Fn14 expression was massively up-regulated in CDE samples and correlated positively with LPC numbers. In primary cell isolates from a CDE liver, all cells positive for the LPC/biliary marker CKpan coexpressed Fn14. We initially suspected that the small proportion of CKpan À /Fn14 þ cells were LPCs reflecting a more hepatocytic gene expression profile and thus negative for the biliary antigen CKpan. However, double staining for other nonparenchymal cell markers with Fn14 yielded an unexpected result: the myofibroblast marker aSMA Sirius red staining and (C) digital quantification showed a spatiotemporal pattern of induction similar to that seen previously with LPC numbers. More specifically, after 2 weeks on the CDE diet, collagen deposition was clearly evident in the periportal areas, where LPC expansion also took place. (E) Associated with this was an increase in expression in collagen-1 mRNA. Additional fibrogenic mediator mRNA expression levels were also increased in the WT CDE liver compared to WT controls: (D) SOX-9, (F) TIMP-1, (G) TIMP-2, and (H) MMP-2 but not (I) MMP-9. Fn14-deficient mice showed a clear attenuation of fibrosis at 2 weeks as measured by (B,C) Sirius red, (E) collagen-1, and (F,G) suppression of TIMP expression. (C,E-G,I) By 3 weeks, this response appeared to have partially rebounded but remained mostly lower than that of WT mice. Data represent means 6 SEM (n ¼ 3-4). Statistical significance is represented as *P < 0.05 and **P < 0.01. The dashed line signifies mRNA levels of control diet-fed WT mice.
colocalized with Fn14 in a subset of cells. The implication of this, at this time, is not entirely clear as a lineage relationship between LPCs and hepatic stellate cells has been proposed. 34 Regardless, we propose that a paracrine TWEAK-Fn14 signaling system operates in LPC-mediated liver regeneration, in which localized secretion of the TWEAK ligand by NK cells and macrophages regulates LPC behavior by binding and activating Fn14 on LPCs.
Another novel finding from our study is the coregulation of inflammation and collagen deposition with LPC responses in TWEAK signaling-deficient mice. Previous studies have suggested that these responses go hand in hand, 4, 22, 35, 36 and again in the present study, we have robustly demonstrated this correlation. We previously hypothesized that inflammatory infiltration precedes the progenitor cell response in CDE-fed mice, 32 and we more recently proposed that initiation of LPC proliferation stimulates activation of hepatic stellate cells and thus matrix remodeling. 4 Interestingly, Van Hul et al. 26 disagree with our proposed sequence; they have suggested that the fibrosis response occurs before LPC expansion. In CDE-fed Fn14 null mice, the hepatic inflammatory response was delayed, and this is consistent with reduced inflammation in cardiotoxin-treated Fn14 null animals in a model of skeletal muscle regeneration. 16 Collagen deposition correlated with the LPC response, with a reduction evident at 2 but not 3 weeks of CDE feeding. If TWEAK is a direct and selective mitogen for LPCs, this implies that fibrosis follows the LPC response and not the other way around. However, as inflammation was coregulated in the Fn14 KO mice, it is not possible from this alone to resolve the relative sequence of the two events.
To demonstrate that TWEAK is a definitive LPC mitogen, development of an in vitro system was essential. In this respect, it is important to note that Jakubowski et al. 8 used a well-differentiated biliary epithelial cell line. We have previously established immortalized LPC lines from WT or transgenic CDE-treated mouse livers and characterized as bipotential murine oval liver (BMOL) cells. 18 As early as 24 hours after TWEAK exposure, growth of the BMOL lines was notably stimulated; this continued for up to 6 days with no plateau apparent. Proliferation was dose-dependent up to 50 ng/mL rhTWEAK; at 100 ng/mL, however, growth was slightly reduced, as was NFjB activation. RNAi experiments have demonstrated the central role of NFjB in mediating Fn14 signaling. When TWEAK binds Fn14, it recruits adaptor molecule TRAF2 (or TRAF5), which activates the NFjB signaling complex and thus results in a long-lasting prosurvival, pro-proliferative response. 12 In accordance with an important role for NFjB in mediating LPC expansion, we found numerous cells expressing both inactive (cytoplasmic) and active (nuclear) NFjB in CDE-treated livers. Considering all this, we suggest that TWEAK signaling, via Fn14 to NFjB, mediates the rapid growth of LPCs in the first 14 days of CDE feeding. These findings are important in the context of manipulating cells for possible therapeutic applications and for future experiments investigating the pro-proliferative and anti-proliferative effects of growth factors and cytokines on LPCs in vitro and in vivo.
In our model, we propose that local production of TWEAK by NK cells and macrophages mediates the expansion of LPCs in chronic injury models, but it is significant that we can show that delivery of exogenous rhTWEAK induces proliferation of periportal CKpanexpressing nonparenchymal cells showing LPC morphology. We detected a mean doubling in proliferating nonparenchymal cells 24 hours after TWEAK administration. By 48 hours, numbers had returned to the baseline. The majority of Ki67 þ nonparenchymal cells ($60%) were LPCs (as judged by their CKpan positivity 24 ). It should be emphasized, however, that this is a conservative estimate, as we have shown previously that in the CDE model, only a subset of LPCs is A6/CKpanpositive. 18 It is therefore likely that some of the Ki67 þ / CK À cells are nonbiliary LPCs. This suggests that it might be possible to augment LPC-mediated liver regeneration with TWEAK, and there are implications for its use in patients with chronic liver disease. However, such studies need to proceed with care, given our findings that a subset of myofibroblasts is also Fn14 þ and thus may also respond to TWEAK stimulation.
In summary, demonstrating definitively that TWEAK is a mitogen for LPCs in vitro and in vivo, this study has confirmed and extended the previous work of Jakubowski et al. 8 On the basis of concurrent analysis of isolated and in situ LPCs, we conclude that the TWEAK signaling system is activated in the chronically injured liver by up-regulated expression of the Fn14 receptor on existing and newly produced LPCs. TWEAK protein is produced and secreted by neighboring NK cells and macrophages and, once bound to Fn14, activates NFjB and, in turn, expression of numerous cell cycle regulatory factors. 1 The behavior of TWEAK is multifaceted, multidimensional, and somewhat schizophrenic, because it modulates a diverse range of cellular processes in different cell types and under different experimental conditions, including proliferation, differentiation, cell migration, cell survival, and cell death (Fig. 1) . 2 The receptor for TWEAK is Fn14 (TNFRSF12A), a member of the fibroblast growth factor-inducible gene family that codes for a 14-kD protein (hence the acronym Fn14). It was identified by differential display, cloned, and sequenced as a type 1 transmembrane protein, but its function was initially unknown. 3 Subsequently, Wiley et al. cloned a gene coding for a TWEAK-binding protein (TWEAK receptor), 4 whose sequence was identical to that reported above 3 and Winkles et al. and Thorgeirsson et al. co-reported that Fn14 is hyperexpressed in liver cancer cell lines and in both human and mouse hepatocellular carcinoma tissues. 5 Furthermore, Fn14 expression, which is very low in the quiescent liver, is induced within 4 hours after two-thirds partial hepatectomy (PH) (a so-called ''immediate early response gene'') and is very highly expressed in several models of mouse hepatocarcinogenesis. 5 This suggested a strong role for TWEAK/ FN14 signaling in proliferation of hepatic epithelial cells and/or their transformation. How this occurs, however, has not been determined. In addition to TNF signaling, the Fn14 receptor is also linked to other cell pathways, such as nuclear factor jB (NFjB), mitogen-activated protein kinase, extracellular signal-regulated kinase, c-Jun N-terminal kinase, and phosphoinositide 3-kinase/AKT, so that the cellular functions regulated at least in part by TWEAK/Fn14 and the mechanisms involved are highly complex.
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TWEAK and Fn14 are expressed in epithelial, mesenchymal, and endothelial cells in many tissues 2 and the pattern of TWEAK/Fn14 expression suggests that this signaling pathway plays an important role in regulating tissue repair and remodeling under both physiologic and pathologic conditions (for an excellent review, see Burkly et al. 6 ). Studies linking TWEAK/ Fn14 signaling to progenitor cell proliferation were first performed in mouse liver, where it was demonstrated that overexpression of TWEAK in transgenic mice causes periportal oval cell hyperplasia. 7 Oval cell expansion in mice can also be induced by administration of 3,5-diethoxycarboxyl-1,4-dihydrocollidine (DDC) and in mice lacking expression of the TWEAK receptor (Fn14-null mice), oval cell proliferation is markedly reduced. 7 In addition, wild-type mice pretreated with a blocking anti-TWEAK monoclonal antibody prior to DDC administration also showed a similar reduction in oval cell expansion. 7 However, TWEAK/Fn14 signaling not only regulates progenitor cell proliferation in hepatic epithelial cells, it also regulates proliferation of mesodermal progenitor cells in the hematopoietic lineage 6 and myogenic progenitor cells (so called ''satellite'' cells) isolated from adult striated muscle tissue and in a tissue regeneration model following muscle injury. 8 From studies conducted over five decades, it has been determined that there are two distinct cellular pathways through which liver regeneration can be achieved. In the normal adult liver, hepatocytes are in a quiescent state and turn over very slowly (only 2-3 times/year). However, following abrupt reduction of liver mass (two-thirds PH) or acute toxic liver injury, hepatocytes rapidly enter the cell cycle and proliferate to restore liver mass within 5-7 days. Many years ago, it was shown during liver regeneration following twothirds PH in a normal young adult rat that periportal hepatocytes initially become labeled with [ 3 H]thymidine, but eventually up to 70%-90% of residual mature hepatocytes throughout the parenchyma engage in DNA synthesis and undergo cell division.
9,10 Liver regeneration is a highly organized, complex, multistep process that involves growth factors and cytokines, gene transcription factors, cell signaling pathways, and expression of cell cycle regulatory genes. [11] [12] [13] From these studies, it has been concluded that the proliferative activity of adult hepatocytes is sufficient to regenerate the liver following two-thirds PH and that there is no evidence that stem cells participate in this process. [11] [12] [13] [14] A second pathway for liver cellular regeneration has been identified when the proliferation of hepatocytes has been blocked by chemical or physical damage to cellular DNA and a regenerative stimulus is applied. This pathway involves proliferation of hepatic epithelial progenitor cells which subsequently differentiate into mature hepatocytes and replace host hepatic mass (originally called ''oval cells'' because of their morphologic appearance 15 ). These cells lie dormant in the canals of Hering (the junctional zone between the biliary tree and the hepatic parenchymal plates) and upon stimulation of liver regeneration under conditions in which hepatocytes cannot proliferate, such as administration of 2-acetaminofluorine (AAF), followed by two-thirds PH, oval/progenitor cells are activated to proliferate, move out into the hepatic parenchyma, and become incorporated into the hepatic lobular structure. 16, 17 In this issue of HEPATOLOGY, Tirnitz-Parker et al. 18 have extended the studies of Jakubowski et al. 7 to show that oval/progenitor cell activation in mice treated with a choline-deficient, ethionine-supplemented (CDE) diet is also mediated by TWEAK/ Fn14 signaling. They showed that TWEAK is produced in the liver by natural killer cells and macrophages, both of which are of mesodermal origin, and that activated oval cells, which express pan-cytokeratin (a liver bile duct and epithelial progenitor cell marker) and Ki67 (a cell proliferation marker), express Fn14. They showed further that clonal mouse liver progenitor cell lines, which have been isolated and characterized extensively in their laboratory, 19 exhibit increased expression of NF-jB after treatment with recombinant human TWEAK and that knockdown of NF-jB expression by small interfering RNA reduces liver progenitor cell proliferation in vitro. These studies demonstrate that TWEAK signaling through a paracrine mechanism leads to the liver progenitor cell response in CDE diet-induced liver injury and regeneration.
Based on the findings that embryos from Fn14 knockout mice appear normal, it has been stated that TWEAK does not play a role in development, presumably including liver development. 6 However, this would seem unlikely given the similarity of gene expression programs in fetal liver stem/progenitor cells and oval/progenitor cells in the adult liver under conditions in which proliferation of adult hepatocytes is blocked. Dabeva and colleagues have reported that TWEAK expression is increased modestly in liver nonparenchymal/Thy1 þ cells of rats treated with 2-AAF/ PH, and Fn14 expression is increased substantially in purified hepatic oval cells from these same animals.
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Fn14 expression is also increased three-fold to fourfold in purified embryonic day 12.5 (ED12.5) fetal mouse liver stem/progenitor cells compared to adult liver, whereas TWEAK expression is very low (see gene expression microarray data at www.ncbi.nlm.nih. gov/ geo; accession number GSE6340). 21 Similar results have been obtained with purified ED14 rat fetal liver stem/progenitor cells (Dabeva and coworkers, unpublished observations).
The most likely explanation for a normal phenotype in embryos from Fn14 null mice is that the functions of the TWEAK/Fn14 pathway can be expressed redundantly by other TNF family members. The most important issues that need to be addressed in future studies are precisely how TWEAK and Fn14 expression are regulated and how can we manipulate expression of this signaling pathway to enhance liver regeneration under conditions in which hepatocyte proliferation is not blocked and/or utilize it to promote liver repopulation by transplanted cells. It is interesting that fetal liver stem/progenitor cells express increased levels of Fn14 and that after transplantation, these cells effectively repopulate the liver following two-thirds PH. Many years ago, it was determined that the regenerative capacity of the liver in rodents decreases with aging 24 and this is presumably true in all mammalian species, including humans. If we could induce expression of the TWEAK/Fn14 pathway, perhaps this would activate human hepatic progenitor cell proliferation and enhance liver regeneration in the aging liver. Moreover, if we could transduce adult hepatocytes with Fn14 and transplant these cells into recipients with a genetic disorder in which there is no hepatic parenchymal pathology, such as in inherited hyperbilirubinemias, ornithine transcarbomylase deficiency, hypercholesterolemia, phenylketonuria, etc., then perhaps we could achieve effective liver repopulation using this strategy.
TNFa, NF-jB, interleukin-6, and signal transducer and activator of transcription 3 (Stat3) are all involved in initiating hepatocyte proliferation during the regenerative response in the normal liver.
11-13 NF-jB also appears to be activated during oval cell activation, and this is mediated by Fn14, the receptor for TWEAK. Because TWEAK is expressed in inflammatory (natural killer) cells and macrophages, 18 there is a direct link between the repair process during and following liver injury and activation of the oval cell/progenitor response. Coordinating these events and their manipulation experimentally could lead to new, interesting, and innovative ways to stimulate liver regeneration, as well as liver repopulation by transplanted cells.
